News for Cyclopharm Limited (CYC.AX)

In a dour end to what’s been a red-washed Week 11, early…

Radiopharmaceutical company Cyclopharm (ASX: CYC) has signed a contract to deploy its flagship product Technegas in as many as 169 nuclear medicine

Cyclopharm (ASX:CYC) has revealed its dosed its first French patients with its technegas lung imaging product in an ongoing trial.

The ASX200 closed up 0.4% – thanks to a very small rise in Australia’s latest Gross Domestic Product data. The Telecommunications sector led, gaining around 2%. Materials shed more than 1.1%

The ASX200 closed the day up 0.8%. All sectors bar one finished…

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +1.65% to 7,178.40.

The ASX200 shed 0.2 of a per cent today as the market awaits the Reserve Bank’s interest rates decision tomorrow.

Cyclopharm (ASX:CYC) has received approval from the United States FDA to commence commercial sales of its novel drug candidate, Technegas.

The US FDA will be coming to inspect Cyclopharm’s facility in Kingsgrove, New South Wales, between 24 July through 4 August.

Treasurer Jim Chalmers has forecast a modest surplus of about $4 billion in tonight’s Budget, the first surplus in 15 years.

Cyclopharm (ASX: CYC) announced the submission today of the formal reply to the US FDA for its proprietary technology, Technegas.

Blood clot was top of biotech news this week after researchers revealed new discovery that could prevent it without risk of bleeding.

McKinsey showed that VCs ploughed US$35 billion into biotechs doing certain programs. Which ASX biotechs are doing similar programs?

Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin